United Therapeutics surges; fourth-quarter sales up 55%

MichaelBaron

NEW YORK (MarketWatch) -- Shares of United Therapeutics Corp.
UTHR, +0.51%
gained 9% to $55.17 after the Silver Spring, Md., biotechnology company reported expanded sales of its Remodulin treatment for pulmonary arterial hypertension in the fourth quarter. Before the opening bell, the company posted earnings of $55.5 million, or $2.42 a share, for the December period, up from a year-ago profit of $29.4 million, or $1.14 a share. Both periods included tax benefits of $47.7 million and $17.5 million, respectively. Revenue rose 55% in the quarter to $45.8 million from $29.6 million a year ago.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.